CD3 epsilon and CD19 bispecific target (CD19xCD3)

The CD3 epsilon and CD19 bispecific target represents a therapeutic strategy that bridges the adaptive immune system's effector cells with malignant or pathogenic B cells. CD3 epsilon is a critical subunit of the T-cell receptor (TCR) complex involved in signal transduction and T-cell activation, while CD19 is a transmembrane protein expressed almost exclusively on the surface of B cells from the early stages of development until differentiation into plasma cells. By targeting both molecules simultaneously, bispecific antibodies or T-cell engagers (BiTEs) can redirect the cytotoxic activity of T cells toward CD19-positive B cells without the need for major histocompatibility complex (MHC) recognition. This approach has proven highly effective in treating B-cell malignancies, such as acute lymphoblastic leukemia and various lymphomas, where CD19 is widely expressed. However, the potent activation of T cells can lead to significant adverse effects, most notably cytokine release syndrome and neurotoxicity, requiring careful clinical management.

Other names

CD19/CD3CD3E/CD19T-cell surface glycoprotein CD3 epsilon chain and B-lymphocyte antigen CD19CD3e and CD19

Bispecific T-cell engager (BiTE) mechanism: simultaneously binds to CD3 epsilon on T cells and CD19 on B cells, bringing them into close proximity to form an immunological synapse. This leads to MHC-independent T-cell activation, release of cytotoxic granules (perforin and granzymes), and subsequent lysis of the target B cell.